Kotlyar Eugene, Keogh Anne M, Thavapalachandran Sujitha, Allada Christopher S, Sharp Jason, Dias Leonora, Muller David
Heart & Lung Transplant Unit, Cardiology Department, St. Vincent's Hospital, Xavier 4, Victoria St, Darlinghurst, NSW 2010, Australia.
Heart Lung Circ. 2005 Dec;14(4):245-51. doi: 10.1016/j.hlc.2005.06.007. Epub 2005 Oct 3.
Contrast agents used in angiography procedures for patients with cardiovascular disease are known to cause contrast-induced nephropathy (CIN), which may be partially due to the production of nephrotoxic oxygen-free radicals. It is uncertain whether administration of intravenous (IV) anti-oxidant, N-acetylcysteine (NAC), can prevent reduction in renal function and whether this is a cost-effective approach.
Sixty-five day-only patients with renal impairment (mean serum creatinine concentration 0.16+/-0.03 mmol/l) due to undergo coronary or peripheral angiography and/or stenting were randomly assigned to IV NAC 300 or 600 mg immediately before and after the procedure or IV fluid alone.
Of the 60 patients with complete data, none had acute CIN (increase in serum creatinine concentration > or = 0.044 mmol/l, 48 h after administration of contrast agent). Eight patients (13%) have demonstrated an increase in their serum creatinine concentration > or = 0.044 mmol/l 30 days after administration of contrast agent: 2/19 (11%) in the control group, 2/21 (10%) in the 600 mg NAC group and 4/20 (20%) the 300 mg NAC group (p = 0.66). The mean volumes of contrast agent used and prehydration given for each of the three groups did not differ significantly (p > 0.83). There was significant improvement in creatinine clearance within each group from baseline to 30 days (p < or = 0.03), but no significant difference between the groups at 48 h and 30 days (p > or = 0.43). Considering the cost of NAC and its administration, we estimate that this would translate to a saving of dollar 26,637 per annum.
For day-stay patients with mild-to-moderate chronic renal impairment undergoing angiography and/or intervention, prehydration alone is less complicated and more cost-effective than a combination of IV NAC (at doses used) and hydration.
已知用于心血管疾病患者血管造影术的造影剂会导致造影剂肾病(CIN),这可能部分归因于肾毒性氧自由基的产生。静脉注射抗氧化剂N-乙酰半胱氨酸(NAC)是否能预防肾功能下降以及这是否是一种具有成本效益的方法尚不确定。
65例因即将接受冠状动脉或外周血管造影和/或支架置入术而出现肾功能损害(平均血清肌酐浓度0.16±0.03 mmol/l)的当日住院患者被随机分配至在手术前后立即静脉注射300或600 mg NAC组或仅静脉输液组。
在60例有完整数据的患者中,无一人发生急性CIN(造影剂给药后48小时血清肌酐浓度升高≥0.044 mmol/l)。8例患者(13%)在造影剂给药后30天血清肌酐浓度升高≥0.044 mmol/l:对照组2/19(11%),600 mg NAC组2/21(10%),300 mg NAC组4/20(20%)(p = 0.66)。三组使用的造影剂平均剂量和给予的预水化量无显著差异(p > 0.83)。每组从基线到30天肌酐清除率均有显著改善(p≤0.03),但在48小时和30天时组间无显著差异(p≥0.43)。考虑到NAC及其给药成本,我们估计每年可节省26,637美元。
对于接受血管造影和/或介入治疗的轻至中度慢性肾功能损害的当日住院患者,单纯预水化比静脉注射NAC(所用剂量)和水化联合应用更简单且更具成本效益。